NDAINJECTIONINJECTABLE
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
CARDIOGEN-82 (rubidium chloride rb-82) by Bracco is 82 is analogous to potassium ion (k) in its biochemical behavior and is extracted by the myocardium in proportion to the blood flow. First approved in 1989.
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDIOGEN-82 is a rubidium chloride Rb-82 injectable radiopharmaceutical used for myocardial perfusion imaging to assess blood flow to the heart. The Rb-82 ion mimics potassium behavior and is extracted by viable myocardium proportional to coronary blood flow, allowing differentiation between healthy and infarcted tissue. It works via Na/K-ATPase pump activity, with radioactivity retained in viable myocardium while clearing from necrotic areas.
LOE Approaching
Product faces approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting a consolidating team focus on retention and operational efficiency.
Mechanism of Action
82 is analogous to potassium ion (K) in its biochemical behavior and is extracted by the myocardium in proportion to the blood flow. Rb participates in the sodium-potassium (Na/K) ion exchange pumps that are present in cell membranes. The intracellular uptake of Rb 82 requires maintenance of ionic…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning at Two Clinical Sites
Started Sep 2011
72 enrolled
Radiation Exposure
Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning
Started Sep 2011
155 enrolled
Radiation Exposure
Why This Matters for Your Career
Worked on CARDIOGEN-82 at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.